GANX Gain Therapeutics, Inc.
$1.20▲ +2.14%
Healthcare
Other
After hours
$1.21▲ +1.49%
Oct 28, 4:46 PM ET
Volume 400.3K
Avg Volume (10D) 816.0K
Key Metrics & Fundamentals
Market Cap
$52.15M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.14 - 4.34
% vs 50 MA
-27.86%
% vs 200 MA
-36.11%
RSI-14
30.4
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.75
Free Cash Flow
-$4.68M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.70M
COGS
–
Operating Exp
$4.68M
Operating Income
-$4.68M
EBIT
-$4.68M
Pretax Income
-$4.57M
Net Income
-$4.68M
EPS (Diluted)
-0.11
Price & Volume History
Loading chart…
Recent News
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
GlobeNewswire · Oct 8, 2026 7:00 AM ET
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
GlobeNewswire · Oct 1, 2026 9:28 AM ET
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
GlobeNewswire · Sep 29, 2026 5:50 PM ET
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
GlobeNewswire · Sep 17, 2026 7:00 AM ET
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Aug 25, 2026 7:00 AM ET
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
GlobeNewswire · Aug 11, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GANX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.